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Abstract
The known breast cancer susceptibility polymorphisms in FGFR2, TNRC9/TOX3, MAP3K1, LSP1, and 2q35
confer increased risks of breast cancer for BRCA1 or BRCA2mutation carriers. We evaluated the associations of 3
additional single nucleotide polymorphisms (SNPs), rs4973768 in SLC4A7/NEK10, rs6504950 in STXBP4/COX11,
and rs10941679 at 5p12, and reanalyzed the previous associations using additional carriers in a sample of 12,525
BRCA1 and 7,409 BRCA2 carriers. Additionally, we investigated potential interactions between SNPs and assessed
the implications for risk prediction. The minor alleles of rs4973768 and rs10941679 were associated with
increased breast cancer risk for BRCA2 carriers (per-allele HR¼ 1.10, 95% CI: 1.03–1.18, P¼ 0.006 and HR¼ 1.09,
95% CI: 1.01–1.19, P¼ 0.03, respectively). Neither SNP was associated with breast cancer risk for BRCA1 carriers,
and rs6504950 was not associated with breast cancer for either BRCA1 or BRCA2 carriers. Of the 9 polymorph-
isms investigated, 7 were associated with breast cancer for BRCA2 carriers (FGFR2, TOX3, MAP3K1, LSP1, 2q35,
SLC4A7, 5p12, P ¼ 7  1011  0.03), but only TOX3 and 2q35 were associated with the risk for BRCA1 carriers
(P ¼ 0.0049, 0.03, respectively). All risk-associated polymorphisms appear to interact multiplicatively on breast
cancer risk for mutation carriers. Based on the joint genotype distribution of the 7 risk-associated SNPs in BRCA2
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mutation carriers, the 5% of BRCA2 carriers at highest risk (i.e., between 95th and 100th percentiles) were
predicted to have a probability between 80% and 96% of developing breast cancer by age 80, compared with 42%
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to 50% for the 5% of carriers at lowest risk. Our findings indicated that these risk differences might be sufficient
to influence the clinical management of mutation carriers. Cancer Res; 70(23); 9742–54. 2010 AACR.
Introduction
Pathogenic mutations in BRCA1 and BRCA2 confer ele-
vated risks of breast and ovarian cancer. Cancer risk esti-
mates have been found to vary by the age at diagnosis and
the cancer site of the proband that led to the family
ascertainment (1–3). Studies have demonstrated significant
variation in the breast cancer risks between families that
segregate mutations in BRCA1 and BRCA2, according to the
strength of family history (2, 4). Such evidence suggests that
genetic or other factors that cluster in families could modify
the cancer risks conferred by BRCA1 and BRCA2 mutations.
Direct evidence of such modifiers of risk has been demon-
strated through recent large-scale association studies con-
ducted by the Consortium of Investigators of Modifiers of
BRCA1/2 (CIMBA; ref. 5). These studies evaluated common
genetic variants (single nucleotide polymorphisms; SNPs)
that have been shown to be associated with breast cancer
risk for women from the general population through gen-
ome-wide association studies (GWAS; refs. 6–9). The CIMBA
studies suggest that of the 6 variants investigated so far
(rs2981582 in FGFR2, rs3803662 in TOX3/TNRC9, rs889312 in
MAP3K1, rs3817198 in LSP1, rs13281615 on 8q24, and
rs13387042 on 2q35), only the TOX3 and 2q35 polymorph-
isms were associated with breast cancer risk for BRCA1
mutation carriers. Five of the polymorphisms, all but the
variant in the 8q24 region, were associated with breast
cancer risk for BRCA2 mutation carriers. The estimated
relative risk for the 8q24 SNP was consistent with that for
the general population, but was not statistically significant.
Since these investigations, 11 other breast cancer suscept-
ibility variants have been identified through GWAS (10–14)
including 3 SNPs, rs4973768 in SLC4A7/NEK10, rs6504950 in
STXBP4/COX11, and rs10941679 on 5p12. To evaluate whether
these 3 polymorphisms are also associated with breast cancer
risk for BRCA1 and BRCA2 mutation carriers we genotyped
these polymorphisms in the CIMBA cohort. We also genotyped
additional mutation carriers for the 6 polymorphisms pre-
viously investigated by CIMBA (6, 7). Here we present the
updated results based on a larger number of female BRCA1 and
BRCA2 mutation carriers. We also evaluated the evidence for
interactions between the variants and the implications for risk
prediction for BRCA1 and BRCA2 mutation carriers.
Materials and Methods
Subjects
Female carriers of pathogenic mutations in BRCA1 and
BRCA2 were recruited through the CIMBA initiative (5).
Thirty-nine studies contributed data for mutation carriers
who were successfully genotyped for 1 or more of the 9 SNPs
investigated. The large majority of carriers were recruited
through cancer genetics clinics offering genetic testing, and
enrolled into national or regional studies. Some carriers were
identified by population-based sampling of cases, and some
by community recruitment (e.g., in Ashkenazi Jewish popula-
tions). Eligibility to participate in CIMBA is restricted to
carriers of pathogenic BRCA1 or BRCA2 mutations who were
18 years or older at recruitment. Information collected
included the year of birth; mutation description, including
nucleotide position and base change; age at last follow-up;
ages at breast and ovarian cancer diagnoses; and age or date
at bilateral prophylactic mastectomy. Information was also
available on the country of residence, defined to be the
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country of the clinic at which the carrier family was recruited
to the study. Related womenwere identified through a unique
family identifier. Women were included in the analysis if they
carried mutations that were pathogenic according to gen-
erally recognized criteria (15). Women who self-reported as
"nonwhite" and those who carried pathogenic mutations in
both BRCA1 and BRCA2 were excluded from the current
analysis. All carriers participated in clinical or research
studies at the host institutions under ethically approved
protocols. Further details of the CIMBA initiative can be
found elsewhere (5).
Genotyping
Genotyping was performed using either the iPLEX or Taq-
man platforms. To ensure genotyping consistency, all geno-
typing centers were required to adhere to the CIMBA
genotyping quality control criteria that are described in detail
in Appendix 1 (Supplementary Material). After excluding
samples that failed quality control, 19,934 unique mutation
carriers (12,525 BRCA1, 7,409 BRCA2) from 39 studies had an
observed genotype for 1 or more of the SNPs and were
included in the analysis (Supplementary Table S1).
Statistical analysis
The aim of the analysis was to evaluate the association
between each genotype and breast cancer risk. The phenotype
of each woman was defined by her age at diagnosis of breast
cancer or her age at last follow-up. For this purpose, women
were censored at the age of the first breast cancer diagnosis,
ovarian cancer diagnosis, or bilateral prophylacticmastectomy
or the age at last observation. Mutation carriers censored at
ovarian cancer diagnosis were considered unaffected. Because
mutation carriers were not sampled randomly with respect to
their disease status, standard methods of survival analysis
(such as Cox regression) may lead to biased estimates of the
hazard ratios (HR; ref. 16). We, therefore, conducted the
analysis by modeling the retrospective likelihood of the
observed genotypes conditional on the disease phenotypes
as previously described (15). The effect of each SNP was
modeled either as a per-allele HR (multiplicative model) or
as separate HR for heterozygotes and homozygotes, and these
were estimated on the log scale. Where there was evidence of
deviation from the multiplicative model, dominant and reces-
sive models were also fitted. The HR were assumed to be
independent of age (i.e., we used a Cox proportional hazards
model). The assumption of proportional hazards was tested by
adding a "genotype age" interaction term to the model to fit
models in which the HR changed with age. Analyses were
carried out using the pedigree analysis software MENDEL (17).
We examined between-study heterogeneity by comparing the
models that allowed for study-specific log-HR against models
in which the same log-HR was assumed to apply to all studies.
All analyses were stratified by study group and country of
residence and used calendar year and cohort-specific breast
cancer incidences for BRCA1 and BRCA2 (4). Risk reducing
salpingo-oophorectomywas not considered in the analysis as it
is not expected to be associated with the underlying SNP
genotype (i.e., it is not a confounder) and previous analyses
of these SNPs suggested no marked effect on the associations
after adjustment (6, 7). We used a robust variance-estimation
approach to allow for the nonindependence of related carriers
(18).
To investigate whether our results were influenced by any of
our assumptions we performed additional sensitivity analyses.
If any of the SNPs were associated with disease survival, the
inclusion of prevalent cases could influence the HR estimates.
We therefore repeated our analysis by excluding mutation
carriers diagnosed more than 5 years prior to the age at
recruitment into the study.
We further investigated for interactions between the SNPs
and estimated the absolute risk of developing breast cancer
based on the joint distribution of all SNPs that were signifi-
cantly associatedwith risk for eitherBRCA1orBRCA2mutation
carriers. Details of these methods are described in Appendix 2.
The proportions of the modifying variance explained by the
set of associated SNPs were estimated by ln(c)/s2, where c is
the estimated coefficient of variation in incidences associated
with SNP (19, 20) and s2 is the estimated modifying variance
(1.32 and 1.73 for BRCA1 and BRCA2 mutation carriers,
respectively; ref. 4). We estimated the total proportion of
the modifying variance due to all SNPs by adding the indivi-
dual proportions, that is, by assuming that the loci combined
multiplicatively.
Results
After the exclusions described in the methods section, a
total of 12,525 BRCA1 and 7,409 BRCA2 mutation carries had
an eligible genotype for at least 1 of the 9 SNPs and were
included in the analysis (total 19,934 mutation carriers, Sup-
plementary Table S1). Of these, 9,933 had an observed geno-
type for all 9 SNPs. Subjects were followed until the first breast
cancer diagnosis (10,546), ovarian cancer diagnosis (1,981), or
bilateral prophylactic mastectomy (567). The remaining sub-
jects were censored at the age they were last observed (6,840).
Only subjects censored at a breast cancer diagnosis were
assumed to be affected in the analysis. Table 1 summarizes
the key characteristics of this CIMBA cohort.
The results for the 3 newly investigated polymorphisms in
the SLC4A7/NEK10, 5p12, and STXBP4/COX11 regions are
shown in Table 2. rs4973768 in SLC4A7/NEK10 was associated
with breast cancer risk for BRCA2 mutation carriers, where
each copy of the minor allele was estimated to confer an HR of
1.10 (95% CI: 1.03–1.18, Ptrend ¼ 0.006). There was no evidence
that this SNP was associated with breast cancer risk for BRCA1
mutation carriers (HR 1.03, Ptrend ¼ 0.26). There was no
evidence of heterogeneity in the study HR estimates (P ¼
0.08 and 0.66 for BRCA1 and BRCA2, respectively; Figs. 1 and 2).
Models that allowed for an age-dependent HR did not fit
better than the models with a constant HR (P ¼ 0.72 and 0.93
for BRCA1 and BRCA2, respectively).
The 5p12 SNP rs10941679 was also associated with breast
cancer risk for BRCA2 mutation carriers (2df P ¼ 0.022 and
Ptrend¼ 0.032). Although the HR estimate for the heterozygote
carriers of the minor allele was greater than the risk for the
homozygote carriers, therewas no significant evidence that the
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heterogeneity model (separate HR parameter for heterozygote
and homozygotes) fit better than the multiplicative model for
the effect of the minor allele of this SNP (P ¼ 0.07). Under the
multiplicativemodel, the per-alleleHRwas estimated to be 1.09
(95% CI: 1.01–1.19, Ptrend ¼ 0.032). A model that assumed that
the underlying model was dominant fitted equally well (HRdo-
minant ¼ 1.15, 95% CI: 1.04–1.27, Pdominant ¼ 0.008). The 5p12 poly-
morphism was not associated with breast cancer for BRCA1
mutation carriers (HR¼ 0.96, 95% CI: 0.90–1.02, Ptrend¼ 0.16).
There was no evidence that the HR vary across studies (Phet¼
0.33 and 0.77 for BRCA1 and BRCA2, respectively; Figs. 1 and 2),
or that the HR vary with age for either BRCA1 or BRCA2
mutation carriers (P ¼ 0.45 and 0.37, respectively).
The STXBP4/COX11 SNP rs6504950 was not associated with
breast cancer risk for either BRCA1 (per-allele HR ¼ 1.02, 95%
CI: 0.96–1.08, Ptrend ¼ 0.59) or BRCA2 mutation carriers (per-
allele HR ¼ 1.03, 95% CI: 0.95–1.11, Ptrend ¼ 0.47). The HR did
not vary significantly with age for either BRCA1 (P ¼ 0.15) or
BRCA2 (P¼ 0.59) mutation carriers. There was no evidence of
heterogeneity in the HR estimates between studies (Phet¼ 0.43
and 0.10 for BRCA1 and BRCA2, respectively; Figs. 1 and 2).
To investigate whether our results may have been biased by
the inclusion of prevalent cancers we repeated the analysis
after excluding carriers diagnosed with breast or ovarian
cancer more than 5 years prior to their recruitment into the
study (i.e., long-term survivors). Individuals from studies in
which the date/age at recruitment was not provided were also
excluded from this analysis. The results for all 3 SNPs are
summarized in Supplementary Table S2. The HR estimates
were very similar to the analysis that included prevalent
cancers. However, the P values were larger and the 5p12
SNP was no longer significantly associated with breast cancer
risk (Ptrend¼ 0.13, Pdominant¼ 0.05) possibly due to the smaller
number of mutation carriers included in this analysis.
The updated results for SNPs, rs2981582 in FGFR2,
rs3803662 in TOX3/TNRC9, rs889312 in MAP3K1, rs3817198
in LSP1, rs13281615 in 8q24, and rs13387042 in 2q35, which
include additional mutation carriers genotyped since they
were originally published, are shown in Table 3. The sample
size increase varied from 1,347 to 1,840 mutation carriers for
the latest published SNPs in LSP1, 8q24, and 2q35 and from
3,413 to 3,854 mutation carriers for SNPs in FGFR2, TOX3/
TNRC9, and MAP3K1. The pattern of associations of these
SNPs with breast cancer risk for BRCA1 and BRCA2mutation
carriers were similar to that found from the previously
published CIMBA analyses, with the same SNPs significantly
associated at the 5% level (6, 7). In the combined set of
BRCA1 mutation carriers, only the TOX3/TNRC9 and 2q35
polymorphisms were associated with risk (Ptrend ¼ 0.0049
and 2df P ¼ 0.01, respectively). In contrast, 5 of the 6 SNPs
were associated with the risk of developing breast cancer in
the combined set of BRCA2 mutation carriers. The most
significant association was for the FGFR2 polymorphism
(Ptrend ¼ 6.8  1011) in which each copy of the minor
allele was estimated to confer an HR of 1.30 (95% CI: 1.20–
1.40), followed by TOX3/TNRC9 (per-allele HR¼ 1.17, 95% CI:
1.07–1.27, Ptrend ¼ 0.00029). These 2 SNPs had the largest
increase in sample size since the previous analysis, and the
significance of each association was correspondingly greater
(Ptrend ¼ 1.7  108 and 0.009 in the previous analysis for
FGFR2 and TOX3/TNRC9, respectively). The significance of
associations between the other SNPs (LSP1, MAP3K1, 2q35)
and breast cancer risk for BRCA2 mutation carriers were
similar to those reported previously (Table 3). The 8q24 SNP
Table 1. Summary characteristics for the 19,934 eligible BRCA1 and BRCA2 carriers used in the analysis
Characteristic BRCA1 BRCA2
Unaffected Breast cancer Unaffected Breast cancer
Number 5,989 6,536 3,399 4,010
Person-years follow-up 255,973 268,566 150,499 150,499
Median age at censure (IQR) 42 (34–51) 40 (35–47) 43 (34–53) 43 (37–50)
Age at censure, N (%)
<30 851 (14.2) 565 (8.6) 485 (14.3) 185 (4.6)
30–39 1,707 (28.5) 2,584 (39.5) 898 (26.4) 1,254 (31.3)
40–49 1,812 (30.3) 2,275 (34.8) 908 (26.7) 1,507 (37.6)
50–59 1,042 (17.4) 833 (12.7) 629 (18.5) 741 (18.5)
60–69 393 (6.6) 219 (3.4) 310 (9.1) 252 (6.3)
70þ 184 (3.1) 60 (0.9) 169 (5.0) 71 (1.8)
Year of birth, N (%)
Before 1920 36 (0.6) 44 (0.7) 30 (0.9) 40 (1.0)
1920–1929 146 (2.4) 212 (3.2) 108 (3.2) 176 (4.4)
1930–1939 388 (6.5) 532 (8.1) 245 (7.2) 437 (10.9)
1940–1949 833 (13.9) 1,349 (20.6) 427 (12.6) 902 (22.5)
1950–1959 1,294 (21.6) 1,945 (29.8) 685 (20.2) 1,145 (28.9)
1960 and later 3,292 (55.0) 2,454 (37.6) 1,904 (56.0) 1,310 (32.7)
Abbreviation: IQR, interquartile range.
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was not associated with breast cancer risk for BRCA2
mutation carriers (per-allele HR ¼ 1.06, 95% CI: 0.98–1.13,
Ptrend ¼ 0.13), but the number of additional BRCA2 mutation
carriers included in this analysis was only 628, and the 95%
CI still included the estimated relative risk in population-
based studies. For all SNPs except TNRC9/TOX3, the inclu-
sion of newly genotyped mutation carriers resulted in some-
what attenuated HR estimates, but narrower CI. The
dominant model remained the most parsimonious model
for the 2q35 SNP for both BRCA1 and BRCA2 carriers.
We evaluated all pairwise interactions between the SNPs
that were associated with breast cancer risks for BRCA1 and
BRCA2 separately (Supplementary Table S3). There was no
evidence of any departure from a log-additive model for the
TOX3/TNRC9 and 2q35 SNPs on the breast cancer risk for
BRCA1 mutation carriers (P ¼ 0.22) or for any pairwise
combination of the 7 SNPs associated with BRCA2 breast
cancer risk (P  0.07).
Figure 3A shows the distribution of the combined HR
across the 7 SNPs associated with breast cancer for BRCA2
mutation carriers, based on the estimates from the CIMBA
sample and assuming that all SNPs interact multiplicatively.
The HR varied from 1 for BRCA2mutation carriers who were
homozygous for the protective allele at all loci, to 5.75 for
those who were homozygous for the risk allele at all loci. The
median, 5th percentile HR, and 95th percentile HR were 1.9,
1.3, and 3.0, respectively. Figure 3B translates the combined
HR into absolute risks of developing breast cancer by age 80.
The estimated risk of developing breast cancer by 80 for
BRCA2 mutation carriers varies from 42% to 96%. The
median cumulative breast cancer risk is 64% (5th and
95th percentile risk 50% and 80%, respectively). Figure 4
shows the age-specific cumulative risks of developing breast
cancer in BRCA2 mutation carriers by the combined geno-
type distribution at the 7 associated SNPs. The risk of
developing breast cancer by age 50 for the 5% of the
Table 2. Genotype frequencies by disease status and hazard ratio estimates
Mutation/gene Genotype Unaffected (%) Affected (%) HR 95% CI P
SLC4A7/NEK10 rs4973768
BRCA1 CC 1,249 (25.8) 1,380 (25.4) 1.00
CT 2,440 (50.4) 2,706 (49.7) 1.00 0.92–1.09
TT 1,155 (23.8) 1,353 (24.9) 1.06 0.96–1.17
2df test 0.40
Per allele 1.03 0.98–1.08 0.26
BRCA2 CC 735 (26.4) 782 (23.2) 1.00
CT 1,359 (48.8) 1,651 (49.0) 1.11 0.98–1.25
TT 689 (24.8) 937 (27.8) 1.22 1.06–1.40
2df test 0.024
Per allele 1.10 1.03–1.18 0.0064
STXBP4/COX11 rs6504950
BRCA1 GG 2,613 (53.5) 2,953 (53.4) 1.00
GA 1,915 (39.2) 2,179 (39.4) 1.01 0.94–1.10
AA 357 (7.3) 385 (7.2) 1.04 0.90–1.19
2df test 0.86
Per allele 1.02 0.96–1.08 0.59
BRCA2 GG 1,556 (55.3) 1,808 (53.2) 1.00
GA 1,054 (37.5) 1,351 (39.7) 1.07 0.97–1.19
AA 203 (7.2) 242 (7.1) 0.99 0.82–1.20
2df test 0.36
Per allele 1.03 0.95–1.11 0.47
5p12 rs10941679
BRCA1 AA 2,490 (56.3) 2,991 (56.7) 1.00
AG 1,626 (36.8) 1,929 (36.6) 0.97 0.89–1.05
GG 304 (6.9) 351 (6.7) 0.90 0.77–1.04
2df test 0.34
Per allele 0.96 0.90–1.02 0.16
BRCA2 AA 1,535 (59.2) 1,809 (55.4) 1.00
AG 900 (34.7) 1,264 (38.7) 1.16 1.04–1.29
GG 156 (6.0) 190 (5.8) 1.05 0.85–1.30
2df test 0.022
Per allele 1.09 1.01–1.19 0.032
Dominant 1.15 1.04–1.27 0.0083
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mutation carriers at lowest risk is between 10% and 13%,
compared with 29% to 47% for the 5% of the mutation
carriers at highest risk. For comparison, we computed the
cumulative risks using a risk score based on the published
per-allele odds ratios (OR) for each SNP (all 9) in population-
based studies (Supplementary Figure S1). The predicted
combined HR and cumulative risks based on the median,
the 5th and 95th percentiles of the genotype distribution
were similar to those based on the CIMBA estimates.
The average risk of developing breast cancer for BRCA1
mutation carriers by age 80 was previously estimated to be
approximately 66% (4). Based on the combined TOX3/
TNRC9–2q35 genotype distribution, 13% of BRCA1 mutation
carriers who were homozygous for the protective allele at
both loci will have a risk of developing breast cancer of 61%,
compared with 72% for the 2% of the BRCA1 mutation
carriers who have the at-risk genotype at both loci.
Discussion
We have investigated 9 breast cancer susceptibility variants
identified through GWAS, for their associations with breast
cancer risk for BRCA1 and BRCA2 mutation carriers. Of the 3
new polymorphisms investigated, the SLC4A7/NEK10 and
5p12 SNPs were associated with breast cancer risk for BRCA2
mutation carriers. For each SNP, the per-allele HR was similar
to the published relative risks in population-based studies. For
BRCA1 mutation carriers, neither SNP showed an association
with breast cancer risk, and in each case the 95% CI for the HR
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excluded the published point estimate for the general popula-
tion. The STXBP4/COX11 SNP was not associated with breast
cancer risk for either BRCA1 or BRCA2 mutation carriers.
However, we cannot rule out that this SNP confers an HR for
breast cancer in BRCA2 mutation carriers similar to the OR
estimated from population-based studies as our CI includes
that estimate (10). Given the magnitude of the effect in
population-based studies, the current CIMBA sample of
BRCA2 mutation carriers would have limited power to detect
such an association (power of 31% at a 0.05 significance level).
The estimated effects were not materially altered by inclusion
of prevalent breast cancers in the analysis.
We have also incorporated newly recruited mutation car-
riers in the analysis of the 6 SNPs that we previously inves-
tigated (FGFR2, TNRC9/TOX3, MAP3K1, LSP1, 8q24, and 2q35;
refs. 6, 7). The conclusions from these analyses were qualita-
tively similar to those previously reported, but there were
some differences in the estimated HR for the risk associated
SNPs. With the exception of TOX3/TNRC9 in BRCA2, the HR
were somewhat attenuated, perhaps reflecting a "winner's
curse" effect (i.e., HR overestimation) in the original investi-
gation (21). The addition of new samples strengthened the
associations for the FGFR2 and TOX3/TNRC9 SNPs, which are
the SNPs with largest estimated HR, but the association P
values increased marginally for the other SNPs.
We focused on the associations of these SNPs with the risk
of breast cancer for BRCA1 and BRCA2 mutation carriers. For
this purpose, individuals who developed ovarian cancer first,
were censored at the ovarian cancer diagnosis and were
assumed to be unaffected in the analysis. If any of these
polymorphisms were associated with ovarian cancer risk, this
could potentially lead to biased estimates of the breast cancer
HR. However, previous analyses of these SNPs, which excluded
mutation carriers who developed ovarian cancer, yielded
similar HR estimates to the analysis that included these
carriers (6). Moreover, there is no evidence from popula-
tion-based studies of ovarian cancer that any of these SNPs
are associated with ovarian cancer risk in the general popula-
tion (22, 23). A separate CIMBA study to estimate the effects of
these polymorphisms on ovarian cancer risk for mutation
carriers, assessed within a competing risks analysis framework
is currently ongoing.
The associations between the 9 SNPs and breast cancer
risk differed substantially between BRCA1 and BRCA2 muta-
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tion carriers. Seven of the polymorphisms were associated
with the risk of developing breast cancer for BRCA2 muta-
tion carriers (FGFR2, TOX3/TNRC9, MAP3K1, LSP1, 2q35,
SLC4A7/NEK10, 5p12). However, despite the larger sample
size for BRCA1 carriers, only TOX3/TNRC9 and 2q35 were
associated with the risk of breast cancer for BRCA1mutation
carriers. Significant differences in the HR between BRCA1
and BRCA2 were observed for FGFR2 (P ¼ 3  106),
MAP3K1 (P ¼ 0.03), and 5p12 (P ¼ 0.01). We have previously
suggested that such differences could be explained by the
differential effects of these SNPs by tumor subtype, speci-
fically by estrogen receptor (ER) status. Analyses by the
Breast Cancer Association Consortium have indicated that
many of the susceptibility loci confer higher relative risks for
ER-positive disease, with weaker or absent association for
ER-negative disease (24). Interestingly, the TOX3 and 2q35
SNPs, which exhibit associations for BRCA1 carriers, show
the strongest evidence for association with ER-negative
breast cancer risk in the general population, consistent with
the observation that BRCA1 tumors are predominantly ER-
negative whereas BRCA2 tumors are predominantly ER-
positive (25). More specifically, these 2 SNPs were the only
SNPs associated significantly with breast cancer expressing
basal markers (M. Garcia-Closas, personal communication),
the predominant subtype of breast cancer in BRCA1 carriers.
The 5p12 and SLC4A7/NEK10 SNPs analyzed in this study
also conferred higher relative risks for ER-positive disease,
consistent with this hypothesis (10, 11). Therefore, our
results provide further evidence for the distinct nature of
the BRCA1 related breast tumors. Overall, the 7 SNPs asso-
ciated with breast cancer risk for BRCA2 mutation carriers
were estimated to account for approximately 4% of the
genetic variability of breast cancer in BRCA2, whereas the
TOX3/TNRC9 and 2q35 were estimated to account for 0.4% of
the genetic variability in breast cancer risk in BRCA1. The
estimated contribution to BRCA1 breast cancer risk varia-
bility is slightly lower than previously estimated (7), as a
result of the attenuated HR estimates in the present analysis.
Table 3. Hazard ratio estimates for previously published associations using additional mutation carriers
Including newly recruited mutation carriers Original analysis (6, 7)
Mutation/SNP Unaffected/
affected
HRa 95% CI Pb Unaffected/
affected
HRa 95% CI Pb
FGFR2 rs2981582
BRCA1 3,822/4,446 1.03 0.97–1.09 0.31 2,874/3,154 1.02 0.95–1.09 0.60
BRCA2 2,160/2,716 1.30 1.20–1.40 6.8  1011 1427/1836 1.32 1.20–1.45 1.7108
TOX3/TNRC9 rs3803662
BRCA1 3,911/4,492 1.09 1.03–1.16 0.0049 3,031/3,263 1.11 1.03–1.19 0.0043
BRCA2 2,135/2,679 1.17 1.07–1.27 0.00029 1,426/1,829 1.15 1.03–1.27 0.009
MAP3K1 rs889312
BRCA1 4,152/4,404 0.99 0.93–1.05 0.63 3,272/3,469 0.99 0.93–1.06 0.86
BRCA2 2,282/2,840 1.10 1.01–1.19 0.022 1,557/1,967 1.12 1.02–1.24 0.020
LSP1 rs3817198
BRCA1 4,480/5,383 1.05 0.99–1.11 0.11 4,203/4,781 1.05 0.99–1.11 0.090
BRCA2 2,636/3,266 1.14 1.06–1.23 0.00079 2404/3030 1.16 1.07–1.25 0.00028
8q24 rs13281615
BRCA1 4,730/5,498 1.00 0.95–1.05 0.93 4,254/4,762 1.00 0.94–1.05 0.88
BRCA2 2,723/3,338 1.06 0.98–1.13 0.13 2,408/3,025 1.06 0.98–1.14 0.15
2q35 rs13387042
BRCA1 4,554/5,383 4,268/4,763
Heterozygotes 1.14 1.04–1.25 1.18 1.07–1.30
Homozygotes 1.05 0.94–1.16 1.08 0.97–1.21
2df test 0.010 0.003
Per allele 1.02 0.96–1.07 0.57 1.03 0.98–1.09 0.24
Dominant 1.11 1.01–1.21 0.026 1.14 1.04–1.25 0.0047
BRCA2 2,646/3,300 2,407/3,042
Heterozygotes 1.16 1.03–1.32 1.21 1.06–1.37
Homozygotes 1.11 0.97–1.28 1.12 0.97–1.31
2df test 0.048 0.015
Per allele 1.05 0.98–1.13 0.17 1.06 0.98–1.14 0.14
Dominant 1.15 1.02–1.29 0.021 1.18 1.04–1.33 0.0079
aPer allele Hazard Ratio unless specified
bMultiplicative model unless specified
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Each variant was estimated to be associated with a
modest HR. The largest per-allele HR estimate was 1.30
for the FGFR2 association for BRCA2 mutation carriers.
However, the combined effect of the susceptibility variants
on risk can be much larger. Analysis of interactions between
pairs of loci indicated that the combined effects were con-
sistent with a multiplicative model. By defining a risk score
based on this assumption, we estimated empirically that the
highest 5% of the risk distribution had an HR of 2.64 (95% CI:
1.83–3.80, P ¼ 2.3  107) compared with the lowest 5%; this
is very close to the predicted HR based on an assumed
multiplicative model. We also conducted a similar analysis
based on the estimated relative risks from population-based
studies, and the quantile-specific risk estimates were similar,
indicating that the HR were not exaggerated due to over-
fitting. Because we only considered pairwise interactions, it
is possible that more complex interactions have been
missed. However, given our results from the pairwise inter-
actions and empirical score analysis, the multiplicative
assumption seems plausible. A model with higher order
interactions could lead to more powerful discrimination,
but even with a study of this size there is insufficient power
to fit higher order interactions reliably.
As BRCA2 mutations confer elevated risks of breast can-
cer, the combined HR estimates translate to large differences
in the absolute risk of developing breast cancer between
genotypes. Based on the combined associations of the 7
SNPs we estimate that the 5% of BRCA2 mutation carriers at
lowest risk will have a lifetime risk of developing breast
cancer of 50% or lower whereas the 5% at highest risk will
have a lifetime risk of 80% or higher. Such differences in risk
could potentially be informative for genetic counseling
purposes for classifying BRCA2 mutation carriers into dif-
ferent risk groups (26). A previous segregation analysis
estimated that, based on the assumed distribution of modi-
fiers of breast cancer risk, BRCA2 mutation carriers at the
5th percentile of risk distribution will have lifetime risk of
developing the disease of 23% and those at the 95th per-
centile will have a lifetime risk of almost 100% (4). This
analysis suggests that much greater improvements in risk
profiling of carriers could be realized in the future if further
modifiers of risk are identified. In contrast to BRCA2, only a
limited number of risk modifying polymorphisms have been
identified for BRCA1. This could reflect the fact that GWAS
have so far focused on breast cancer patients unselected for
tumor subtypes. Ongoing GWAS in BRCA1 mutation carriers
and in ER-negative disease in the general population will be
valuable in this respect.
In summary, our results indicate that the majority of the
common breast cancer susceptibility variants identified
through GWAS are associated with breast cancer risk for
BRCA2 mutation carriers, to a similar relative extent as in
the general population. Their combined association results
in substantial risk differences in absolute risk across SNP
genotype categories. Such differences could inform genetic
counseling and lead to improved management of mutation
carriers. Future studies in both the general population and
mutation carriers that include GWAS, denser genotyping,
exome, and whole genome sequencing are likely to identify
further variants associated with cancer risk for mutation
carriers and will ultimately lead to more accurate risk
prediction for these women.
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Figure 3. A, cumulative distribution function of the combined hazard
ratio for breast cancer risk for BRCA2 mutation carriers at SNPs:
rs2981582 in FGFR2, rs3803662 in TOX3/TNRC9, rs889312 in MAP3K1,
rs3817198 in LSP1, rs13387042 in 2q35 region, rs4973768 in
SLC4A7/NEK10, and rs10941679 in the 5p12 region (see Materials and
Methods for definition of combined HR). B, predicted cumulative risk of
developing breast cancer by age 80 for BRCA2 mutation carriers by
the combined HR at the above SNPs.
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